Variations in Insurances Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD.

Variations in Insurances Policies Regarding Adherence to the AGA Guideline for Therapeutic Drug Monitoring in IBD. J Clin Gastroenterol. 2018 Nov 14;: Authors: Yadav A, Vasquez P, Dolgin NH, Falchuk KR, Feuerstein JD Abstract BACKGROUND: The American Gastroenterological Association (AGA) published guidelines on therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD) in August 2017 recommending use of reactive TDM to guide treatment changes in patients with active IBD who are being treated with anti-tumor necrosis factor (anti-TNF) agents or thiopurines. We sought to determine if changes in national clinical…

Read More

Utility of DNA Flow Cytometric Analysis of Paraffin-Embedded Tissue in the Risk Stratification and Management of “Indefinite for Dysplasia” in Patients with Inflammatory Bowel Disease.

Utility of DNA Flow Cytometric Analysis of Paraffin-Embedded Tissue in the Risk Stratification and Management of “Indefinite for Dysplasia” in Patients with Inflammatory Bowel Disease. J Crohns Colitis. 2018 Nov 13;: Authors: Wen KW, Rabinovitch PS, Wang D, Huang D, Mattis AN, Choi WT Abstract Background and Aims: The clinical significance of “indefinite for dysplasia” (IND) in patients with inflammatory bowel disease remains unclear. Currently, no biomarker can reliably differentiate reactive changes from true dysplasia and/or risk stratify IND. Methods: Fifty-two IND colon biopsies were analyzed by DNA flow cytometry.…

Read More

Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets.

Damage-associated molecular patterns in inflammatory bowel disease: From biomarkers to therapeutic targets. World J Gastroenterol. 2018 Nov 07;24(41):4622-4634 Authors: Nanini HF, Bernardazzi C, Castro F, de Souza HSP Abstract The chronic inflammatory process underlying inflammatory bowel disease (IBD), comprising Crohn’s disease and ulcerative colitis, derives from the interplay of several components in a genetically susceptible host. These components include environmental elements and gut microbiota a dysbiosis. For decades, immune abnormalities have been investigated as critically important in IBD pathogenesis, and attempts to develop effective therapies have predominantly targeted the immune…

Read More

Authors’ reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn’s Disease Behavior, Fecal Calprotectin and Quality of Life.

Authors’ reply: The Association Between Visceral Adipose Tissue and Stricturing Crohn’s Disease Behavior, Fecal Calprotectin and Quality of Life. Inflamm Bowel Dis. 2018 Oct 31;: Authors: Bryant RV, Schultz CG, Ooi S, Goess C, Costello SP, Vincent AD, Schoeman S, Lim A, Bartholomeusz FD, Travis SPL, Andrews JM PMID: 30380064 [PubMed – as supplied by publisher] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/30380064?dopt=Abstract

Read More

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-Personalised medicine in its infancy.

Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-Personalised medicine in its infancy. Aliment Pharmacol Ther. 2018 Oct 30;: Authors: Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’Haens GR Abstract BACKGROUND: Inflammatory bowel disease (IBD) is characterised by substantial heterogeneity in treatment response. With an expanding number of therapeutic agents, identifying optimal treatment at the patient level remains a major challenge. AIM: To systematically review the available literature on predictive biomarkers of therapeutic response in IBD. METHODS: An electronic literature search was performed…

Read More

The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn’s and Colitis Foundation.

The Role of Cannabis in the Management of Inflammatory Bowel Disease: A Review of Clinical, Scientific, and Regulatory Information: Commissioned by the Crohn’s and Colitis Foundation. Inflamm Bowel Dis. 2018 Oct 24;: Authors: Swaminath A, Berlin EP, Cheifetz A, Hoffenberg E, Kinnucan J, Wingate L, Buchanan S, Zmeter N, Rubin DT Abstract There is significant interest among patients and providers in using cannabis (marijuana) and its derivatives to treat a number of chronic illnesses, including inflammatory bowel disease. Despite the Schedule I classification of cannabis by the federal government, state…

Read More

Appropriateness of Biologics in the Management of Crohn’s Disease Using RAND/UCLA Appropriateness Methodology.

Appropriateness of Biologics in the Management of Crohn’s Disease Using RAND/UCLA Appropriateness Methodology. Inflamm Bowel Dis. 2018 Oct 19;: Authors: Weizman AV, Nguyen GC, Seow CH, Targownik L, Murthy SK, Boland K, Afzal NM, Khanna R, Jones J, Afif W, Halder S, Reinglas J, Fowler S, Huang V, Kaplan GG, Melmed GY Abstract Background: 3 classes of biologics are now available for the treatment of Crohn’s disease. The availability of multiple treatment options has led to questions regarding the appropriateness of each agent for a given patient. We aimed to…

Read More

Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis.

Related Articles Practical fecal calprotectin cut-off value for Japanese patients with ulcerative colitis. World J Gastroenterol. 2018 Oct 14;24(38):4384-4392 Authors: Urushikubo J, Yanai S, Nakamura S, Kawasaki K, Akasaka R, Sato K, Toya Y, Asakura K, Gonai T, Sugai T, Matsumoto T Abstract AIM: To determine appropriate fecal calprotectin cut-off values for the prediction of endoscopic and histologic remission in Japanese patients with ulcerative colitis (UC). METHODS: We performed a cross-sectional observational study of 131 Japanese patients with UC and measured fecal calprotectin levels by fluorescence enzyme immunoassay. The clinical…

Read More
<< Go Back